INS and metabolic dysfunction-associated steatotic liver disease: In the liver, BPA increased de novo lipogenesis by inhibiting miR192, consequently leading to the development of nonalcoholic fatty liver disease (NAFLD).[2a] By targeting Pdx‐1, miR338 controlled the BPA‐induced pancreatic insulin secretory of epigenetic information transmission, some miRNAs have been reported to exhibit consistent changes in the liver of father‐offspring pairs of animals.